Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Objective: To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective. Design: A within-trial cost-util...

Full description

Bibliographic Details
Main Authors: Dakin, H.A (Author), Wordsworth, S. (Author), Rogers, C.A (Author), Abangma, G. (Author), Raftery, J. (Author), Harding, S.P (Author), Lotery, A.J (Author), Downes, S.M (Author), Chakravarthy, U. (Author), Reeves, B.C (Author)
Format: Article
Language:English
Published: 2014-07-29.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items